Saba Husain
Eli Lilly and Company
16 Papers
199 Citations
Saba Husain is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Melanocortin & Receptor. The author has an hindex of 12, co-authored 16 publications. Previous affiliations of Saba Husain include Albany Molecular Research, Inc..
Chat about Author
Papers
Open Innovation for Phenotypic Drug Discovery The PD2 Assay Panel
Jonathan A. Lee,Shaoyou Chu,Francis S. Willard,Karen Leigh Cox,Rachelle J. Sells Galvin,Robert B. Peery,Sarah E. Oliver,Jennifer Oler,Tamika D. Meredith,Steven A. Heidler,Wendy H. Gough,Saba Husain,Alan David Palkowitz,Christopher M. Moxham +13 more
TL;DR: Screening results for the first 4691 compounds submitted to PD2 have confirmed hit rates from 1.6% to 10%, with the majority of active compounds exhibiting acceptable potency and selectivity, indicating that chemical diversity from open source collaborations complements internal sources.
55
A Novel and Selective β-Melanocyte-Stimulating Hormone-Derived Peptide Agonist for Melanocortin 4 Receptor Potently Decreased Food Intake and Body Weight Gain in Diet-Induced Obese Rats
Hansen M. Hsiung,Jeanne L. Hertel,Xing-Yue Zhang,Dennis P. Smith,David L. Smiley,Mark L. Heiman,Derek D. Yang,Saba Husain,John P. Mayer,Lianshan Zhang,Huaping Mo,Liang Zeng Yan +11 more
TL;DR: Subcutaneous or intracerebroventricular administration of peptide 6 in rats showed potent in vivo efficacy as evidenced by its effects in reducing energy balance, increasing fat use, and decreasing weight gain in both acute and chronic rat metabolic studies.
31
Privileged structure-based ligands for melanocortin receptors—tetrahydroquinolines, indoles, and aminotetralines
Matthew J. Fisher,Ryan Thomas Backer,Saba Husain,Hansen M. Hsiung,Jeffrey T. Mullaney,Thomas P. O’Brian,Paul L. Ornstein,Roger Ryan Rothhaar,John M. Zgombick,Karin Briner +9 more
TL;DR: Substitution of the aryl sulfonamide moiety contained in MC4 agonist 1 with bicyclic heterocycles and aminotetralines produced compounds with MC4 activity.
27
Discovery of a β-MSH-derived MC-4R selective agonist
John P. Mayer,Hansen M. Hsiung,David B. Flora,Patrick Edwards,Dennis P. Smith,Xing-Yue Zhang,Robert Alan Gadski,Mark L. Heiman,Jeanne L. Hertel,Paul J. Emmerson,Saba Husain,Thomas P. O’Brien,Steven D. Kahl,David L. Smiley,Lianshan Zhang,Richard D. DiMarchi,Liang Zeng Yan +16 more
TL;DR: A series of novel, disulfide-constrained human beta-melanocyte stimulating hormone (beta-MSH)-derived peptides were optimized for in vitro melanocortin-4 receptor (MC-4R) binding affinity, agonist efficacy, and selectivity.
24
Novel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly Accessible Panel of Assays
Jonathan A. Lee,Paul Shinn,Susan Jaken,Sarah E. Oliver,Francis S. Willard,Steven A. Heidler,Robert B. Peery,Jennifer Oler,Shaoyou Chu,Noel Southall,Thomas S. Dexheimer,Jeffrey K. Smallwood,Ruili Huang,Rajarshi Guha,Ajit Jadhav,Karen Cox,Christopher P. Austin,Anton Simeonov,G. Sitta Sittampalam,Saba Husain,Natalie Franklin,David J. Wild,Jeremy J. Yang,Jeffrey J. Sutherland,Craig J. Thomas +24 more
TL;DR: Phenotypic outcomes for numerous drugs were confirmed, including sulfonylureas as insulin secretagogues and the anti-angiogenesis actions of multikinase inhibitors sorafenib, axitinib and pazopanib and several novel outcomes were also noted including the Wnt potentiating activities of rotenone and the antifolate class of drugs.